TY - JOUR AU - Piliero, P. J. PY - 2002 DA - 2002// TI - Atazanavir: a novel HIV-1 protease inhibitor JO - Expert Opin Investig Drugs VL - 11 UR - https://doi.org/10.1517/13543784.11.9.1295 DO - 10.1517/13543784.11.9.1295 ID - Piliero2002 ER - TY - JOUR AU - Moyle, G. PY - 2002 DA - 2002// TI - Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens JO - AIDS Patient Care STDs VL - 16 UR - https://doi.org/10.1089/108729102761882125 DO - 10.1089/108729102761882125 ID - Moyle2002 ER - TY - JOUR AU - Clercq, E. PY - 2002 DA - 2002// TI - Highlights in the development of new antiviral agents JO - Mini Rev Med Chem VL - 2 UR - https://doi.org/10.2174/1389557024605474 DO - 10.2174/1389557024605474 ID - Clercq2002 ER - TY - JOUR AU - Havlir, D. V. AU - O’Marro, S. D. PY - 2004 DA - 2004// TI - Atazanavir: new option for treatment of HIV infection JO - Clin Infect Dis VL - 38 UR - https://doi.org/10.1086/420932 DO - 10.1086/420932 ID - Havlir2004 ER - TY - JOUR AU - Focà, E. PY - 2012 DA - 2012// TI - Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use JO - Drugs VL - 72 UR - https://doi.org/10.2165/11631070-000000000-00000 DO - 10.2165/11631070-000000000-00000 ID - Focà2012 ER - TY - JOUR AU - Giuntini, R. PY - 2010 DA - 2010// TI - Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study JO - HIV Med VL - 11 UR - https://doi.org/10.1111/j.1468-1293.2009.00740.x DO - 10.1111/j.1468-1293.2009.00740.x ID - Giuntini2010 ER - TY - JOUR AU - Torti, C. PY - 2009 DA - 2009// TI - Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts JO - Infection VL - 37 UR - https://doi.org/10.1007/s15010-008-8010-6 DO - 10.1007/s15010-008-8010-6 ID - Torti2009 ER - TY - JOUR AU - McNicholl, I. R. PY - 2004 DA - 2004// TI - Drug Interactions Among the Antiretrovirals JO - Curr Infect Dis Rep VL - 6 UR - https://doi.org/10.1007/s11908-996-0013-9 DO - 10.1007/s11908-996-0013-9 ID - McNicholl2004 ER - TY - JOUR AU - Pavie, J. PY - 2011 DA - 2011// TI - Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy JO - J Antimicrob Chemother VL - 66 UR - https://doi.org/10.1093/jac/dkr316 DO - 10.1093/jac/dkr316 ID - Pavie2011 ER - TY - STD TI - Ministero della Salute. Linee guida italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnositico-clinica delle persone con infezione da HIV-1. 2015; Available from: www.salute.gov.it/imgs/C_17_pubblicazioni_2442_allegato.pdf. Accessed 1 Feb 2017. UR - http://www.salute.gov.it/imgs/C_17_pubblicazioni_2442_allegato.pdf ID - ref10 ER - TY - STD TI - Torti C, et al. Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). Int J Epidemiol. 2015. [Epub ahead of print]. ID - ref11 ER - TY - JOUR AU - Postorino, M. C. PY - 2015 DA - 2015// TI - Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort JO - Clin Microbiol Infect VL - 21 UR - https://doi.org/10.1016/j.cmi.2014.10.022 DO - 10.1016/j.cmi.2014.10.022 ID - Postorino2015 ER - TY - JOUR AU - Mondi, A. PY - 2015 DA - 2015// TI - Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study JO - J Antimicrob Chemother VL - 70 UR - https://doi.org/10.1093/jac/dkv037 DO - 10.1093/jac/dkv037 ID - Mondi2015 ER - TY - JOUR AU - Giambenedetto, S. PY - 2013 DA - 2013// TI - Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) JO - J Antimicrob Chemother VL - 68 UR - https://doi.org/10.1093/jac/dkt007 DO - 10.1093/jac/dkt007 ID - Giambenedetto2013 ER - TY - JOUR AU - Souza, S. J. PY - 2013 DA - 2013// TI - Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review JO - Rev Assoc Med Bras VL - 59 UR - https://doi.org/10.1016/j.ramb.2012.11.003 DO - 10.1016/j.ramb.2012.11.003 ID - Souza2013 ER - TY - JOUR AU - Young, B. PY - 2013 DA - 2013// TI - Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES JO - AIDS Res Hum Retroviruses VL - 29 ID - Young2013 ER - TY - JOUR AU - Colafigli, M. PY - 2008 DA - 2008// TI - Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen JO - HIV Med VL - 9 UR - https://doi.org/10.1111/j.1468-1293.2007.00541.x DO - 10.1111/j.1468-1293.2007.00541.x ID - Colafigli2008 ER - TY - JOUR AU - Nguyen, S. T. PY - 2008 DA - 2008// TI - Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus JO - Pharmacotherapy VL - 28 UR - https://doi.org/10.1592/phco.28.3.323 DO - 10.1592/phco.28.3.323 ID - Nguyen2008 ER - TY - JOUR AU - Postorino, M. C. PY - 2016 DA - 2016// TI - Exploratory analysis for the evaluation of estimated glomerular filtration rate, Cholesterol and triglycerides after switching from tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in patients with preserved renal function JO - Open AIDS J VL - 10 UR - https://doi.org/10.2174/1874613601610010136 DO - 10.2174/1874613601610010136 ID - Postorino2016 ER - TY - JOUR AU - Ferraris, L. PY - 2012 DA - 2012// TI - Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers JO - J Antimicrob Chemother VL - 67 UR - https://doi.org/10.1093/jac/dks175 DO - 10.1093/jac/dks175 ID - Ferraris2012 ER - TY - JOUR AU - Calza, L. PY - 2013 DA - 2013// TI - Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir JO - Scand J Infect Dis VL - 45 UR - https://doi.org/10.3109/00365548.2012.712213 DO - 10.3109/00365548.2012.712213 ID - Calza2013 ER - TY - JOUR AU - Tanaka, H. PY - 2013 DA - 2013// TI - Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients JO - J Pharm Pharm Sci VL - 16 UR - https://doi.org/10.18433/J32P5C DO - 10.18433/J32P5C ID - Tanaka2013 ER - TY - JOUR AU - Calza, L. PY - 2012 DA - 2012// TI - Renal toxicity associated with antiretroviral therapy JO - HIV Clin Trials VL - 13 UR - https://doi.org/10.1310/hct1304-189 DO - 10.1310/hct1304-189 ID - Calza2012 ER - TY - JOUR AU - Quiros-Roldan, E. PY - 2016 DA - 2016// TI - Neutrophil to lymphocyte ratio and cardiovascular disease incidence in HIV-infected patients: a population-based cohort study JO - PLoS ONE VL - 11 UR - https://doi.org/10.1371/journal.pone.0154900 DO - 10.1371/journal.pone.0154900 ID - Quiros-Roldan2016 ER - TY - JOUR AU - Raffetti, E. PY - 2015 DA - 2015// TI - The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study JO - Infect Agent Cancer VL - 10 UR - https://doi.org/10.1186/s13027-015-0032-y DO - 10.1186/s13027-015-0032-y ID - Raffetti2015 ER - TY - JOUR AU - Mendeni, M. PY - 2011 DA - 2011// TI - Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection JO - Clin Infect Dis VL - 52 UR - https://doi.org/10.1093/cid/cir071 DO - 10.1093/cid/cir071 ID - Mendeni2011 ER - TY - JOUR AU - Focà, E. PY - 2016 DA - 2016// TI - Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study JO - Medicine (Baltimore) VL - 95 UR - https://doi.org/10.1097/MD.0000000000004091 DO - 10.1097/MD.0000000000004091 ID - Focà2016 ER - TY - JOUR AU - Levey, A. S. PY - 2009 DA - 2009// TI - A new equation to estimate glomerular filtration rate JO - Ann Intern Med VL - 150 UR - https://doi.org/10.7326/0003-4819-150-9-200905050-00006 DO - 10.7326/0003-4819-150-9-200905050-00006 ID - Levey2009 ER - TY - JOUR AU - Sterling, R. K. PY - 2006 DA - 2006// TI - Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection JO - Hepatology VL - 43 UR - https://doi.org/10.1002/hep.21178 DO - 10.1002/hep.21178 ID - Sterling2006 ER - TY - JOUR AU - Nordell, A. D. PY - 2014 DA - 2014// TI - Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation JO - J Am Heart Assoc VL - 3 UR - https://doi.org/10.1161/JAHA.114.000844 DO - 10.1161/JAHA.114.000844 ID - Nordell2014 ER - TY - JOUR AU - McComsey, G. A. PY - 2014 DA - 2014// TI - Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202 JO - J Acquir Immune Defic Syndr VL - 65 UR - https://doi.org/10.1097/01.qai.0000437171.00504.41 DO - 10.1097/01.qai.0000437171.00504.41 ID - McComsey2014 ER - TY - JOUR AU - Raffetti, E. PY - 2015 DA - 2015// TI - The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study JO - J Transl Med VL - 13 UR - https://doi.org/10.1186/s12967-015-0446-8 DO - 10.1186/s12967-015-0446-8 ID - Raffetti2015 ER - TY - JOUR AU - Raffetti, E. PY - 2015 DA - 2015// TI - Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study JO - J Acquir Immune Defic Syndr VL - 69 UR - https://doi.org/10.1097/QAI.0000000000000682 DO - 10.1097/QAI.0000000000000682 ID - Raffetti2015 ER - TY - JOUR AU - Biyik, M. PY - 2013 DA - 2013// TI - Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis JO - Eur J Gastroenterol Hepatol VL - 25 UR - https://doi.org/10.1097/MEG.0b013e32835c2af3 DO - 10.1097/MEG.0b013e32835c2af3 ID - Biyik2013 ER - TY - JOUR AU - Tahan, V. PY - 2008 DA - 2008// TI - Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk JO - Hepatogastroenterology VL - 55 ID - Tahan2008 ER - TY - JOUR AU - Mocroft, A. PY - 2010 DA - 2010// TI - Serious fatal and nonfatal non-AIDS-defining illnesses in Europe JO - J Acquir Immune Defic Syndr VL - 55 UR - https://doi.org/10.1097/QAI.0b013e3181e9be6b DO - 10.1097/QAI.0b013e3181e9be6b ID - Mocroft2010 ER - TY - JOUR AU - Quiros-Roldan, E. PY - 2016 DA - 2016// TI - Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 JO - AIDS Care VL - 28 UR - https://doi.org/10.1080/09540121.2016.1198750 DO - 10.1080/09540121.2016.1198750 ID - Quiros-Roldan2016 ER - TY - JOUR AU - Hasse, B. PY - 2015 DA - 2015// TI - Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population JO - Open Forum Infect Dis VL - 2 UR - https://doi.org/10.1093/ofid/ofv108 DO - 10.1093/ofid/ofv108 ID - Hasse2015 ER - TY - JOUR AU - Saumoy, M. PY - 2016 DA - 2016// TI - Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk JO - Atherosclerosis VL - 246 UR - https://doi.org/10.1016/j.atherosclerosis.2016.01.014 DO - 10.1016/j.atherosclerosis.2016.01.014 ID - Saumoy2016 ER -